High-throughput screening identifies cardiac glycosides as potent inhibitors of human tissue kallikrein expression: Implications for cancer therapies

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5778-5784

  Prassas, Ioannis ^a,b   Paliouras, Miltiadis ^a,b   Datti, Alessandro ^c   Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONVALLATOXIN; DIGITOXIGENIN; DIGITOXIN; DIGOXIN; KALLIKREIN 5; KALLIKREIN 6; MYC PROTEIN; OUABAIN; PERUVOSIDE; PROTEIN C FOS; TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT; CARDIAC GLYCOSIDE; TISSUE KALLIKREIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BREAST TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE LIBRARY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIAC GLYCOSIDES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; TISSUE KALLIKREINS; TRANSCRIPTION, GENETIC;

EID: 53249090605     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0706     Document Type: Article

References (42)

1. Doyle DM, Miller KD. Development of new targeted therapies for breast cancer. Breast Cancer 2008:15: 49-56.
2. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006;5:785-99.
3. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000:291: 113-35.
4. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem 2005;1:71-104.
5. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79.
6. Shaw JL, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007;53:1423-32.
7. Borgono CA, Michael IP, Komatsu N, et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 2007;282: 3640-52.
8. Malm J, Hellman J, Hogg P, et al. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate 2000;45:132-9.
9. Yousef GM, Kishi T, Diamandis EP. Role of kallikrein enzymes in the central nervous system. Clin Chim Acta 2003;329:1-8.
10. Borgono CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-80.
11. Yamasaki K, Schauber J, Coda A, et al. Kallikreinmediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J 2006;20:2068-80.
12. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
13. Komatsu N, Takata M, Otsuki N, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol 2002;118:436-43.
14. Komatsu N, Saijoh K, Kuk C, et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br J Dermatol 2007;156: 875-83.
15. Hansson L, Backman A, Ny A, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J Invest Dermatol 2002;118:444-9.
16. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975-80.
17. Zhang JH, ChungTD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
18. Keseru GM, Makara GM. Hit discovery and hit-tolead approaches. Drug Discov Today 2006;11:741-8.
19. Seiler KP, George GA, Happ MP, et al. Chem-Bank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res 2008; 36:D351-9.
20. Paliouras M. Diamandis EP. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006;387:643-52.
21. Smith TW. The fundamental mechanism of inotropic action of digitalis. Therapie 1989;44:431-5.
22. Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2007;123:138-46.
23. MijatovicT, Van Quaquebeke E, Delest B, et al. Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta 2007;1776:32-57.
24. Winnicka K, Bielawski K, Bielawska A. Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm 2006;63:109-15.
25. Stenkvist B, Bengtsson E, Eriksson O, et al. Cardiac glycosides and breast cancer. Lancet 1979;1:563.
26. Stenkvist B. Cardenolides and cancer. Anticancer Drugs 2001;12:635-8.
27. Kometiani P, Liu L, Askari A. Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. Mol Pharmacol 2005;67:929-36.
28. Huang YT, Chueh SC, Teng CM, et al. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 2004;67:727-33.
29. Newman RA, Yang P, Hittelman WN, et al. Oleandrin-mediated oxidative stress in human melanoma cells. J ExpTher Oncol 2006;5:167-81.
30. Newman RA, Kondo Y, Yokoyama T, et al. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 2007;6:354-64.
31. Frese S, Frese-Schaper M, Andres AC, et al. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006;66:5867-74.
32. Kawazoe N, Watabe M, Masuda Y, et al. Tiaml is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 1999; 18:2413-21.
33. Kulikov A, Eva A, Kirch U, et al. Ouabain activates signaling pathways associated with cell death in human neuroblastoma. Biochim Biophys Acta 2007; 1768:1691-702.
34. Lopez-Lazaro M, Pastor N, Azrak SS, et al. Digitoxm inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod 2005;68:1642-5.
35. Mekhail T Kaur H. Ganapathi R, et al. Phase 1 trial of Anvirzel in patients with refractory solid tumors. Invest New Drugs 2006;24:423-7.
36. Xie Z, Askari A. Na(+)/K(+)-ATPase as a signal transducer. Eur J Biochem 2002;269:2434-9.
37. Johnson PH, Walker RP, Jones SW, et al. Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells. Mol CancerTher 2002;1:1293-304.
38. MijatovicT, De Neve N, Mathieu V, et al. Cardenolide mediated c-Myc down-regulation in human cancer cell lines. American Association for Cancer Research (AACR) 2007 Annual meeting poster no. 2089, Los Angeles, CA, April 14-18, 2007.
39. Robson S, Pelengaris S, Khan M. c-Myc and downstream targets in the pathogenesis and treatment of cancer. Rec Patents Anticancer Drug Discov 2006;1: 305-26.
40. Hermeking H. The MYC oncogene as a cancer drug target. Curr Cancer Drug Targets 2003;3:163-75.
41. Dang CV. O'Donnell KA, Zeller Kl, et al. The c-Myc target gene network. Semin Cancer Biol 2006;16: 253-64.
42. Mao DY, Watson JD, Yan PS, et al. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol 2003;13:882-6.